CoLucid Pharmaceuticals, Inc. CLCD was a big mover last session, as the company saw its shares rise over 7% on the day. The upside came after the company provided an interim update from a phase III long-term, open-label trial evaluating lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura. The news led to far more shares changing hands than in a normal session resulting in solid volume. This continues the recent uptrend for the company as the stock is now up 246.7% in the past one-month time frame.
None of the estimates for this stock were revised over the past seven days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
CoLucid Pharmaceuticals currently carries a Zacks Rank #4 (Sell), while its Earnings ESP is 0.00%.
A better-ranked stock in the same industry is ANI Pharmaceuticals, Inc. ANIP, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Zacks Investment Research